Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + Camrelizumab + Apatinib in MPLC
NCT04201990Phase 2Unknown
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in multiple primary lung cancer (MPLC). Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
multiple primary lung cancer (MPLC)
Beyond the preview
Go deeper on NCT04201990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201990.